Symbiotec Pharmalab files DRHP with SEBI for IPO aggregating upto Rs 2180 Cr

image credit- freepik

Indore-based Symbiotec Pharmalab, a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables, has filed its Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI).

The company plans to raise funds through offer of equity shares (face value Rs 2 each) through initial public offerings aggregating up to Rs 2,180 crore. The offer comprises of fresh issue of equity shares aggregating up to Rs 150 crore (The Fresh Issue) and offer for sale by Selling Shareholders aggregating up to Rs 2,030 crore (The Offer for Sale).

The company plans to utilise fund raised through net proceeds on a.) Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company and b.) General corporate purposes.

Symbiotec Pharmalab Limited has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs) in volume terms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidal-hormone APIs. (Source: F&S Report). It is the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in Fiscal 2025, (Source: F&S Report) demonstrating the depth of company’s portfolio.

The company manufactures these products using fermentation and multi-step complex chemical reactions. With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea and other global organisations.